Welcome

Advanced Innovative Partners is a radiopharmaceutical company committed to advancing the field of healthcare through novel diagnostic and therapeutic innovations. We specialize in the development of technologies for oncology, rare pediatric diseases, infectious diseases, and biomedical countermeasures. Our mission is to provide clinicians with the tools they need to better understand and manage complex diseases, ultimately improving therapeutic outcomes.

Roseanne Satz, Chief Executive Officer

ABOUT US

Advanced Innovative Partners (AIP) is a clinical-stage biotechnology company founded in 2017 with a highly skilled team that has developed patented platform technologies for treatment and clinical management in oncology, rare pediatric diseases, infectious diseases, and biomedical countermeasures.

We are building a vertically integrated radiopharmaceutical company with our lead programs in Phase I/II/III clinical trials. We have established a leadership position in the emerging radiopharmaceutical diagnostics and therapeutics market space through a product-centric approach and have created a pipeline of multiple drugs in areas with significant market opportunities.

Our technology has a promising role in cancer and infectious diseases. AIP’s developments focus on understanding the role of integrins, a family of cell surface receptors, in both cancer progression and infectious disease pathogenesis. Using advanced imaging techniques, we track integrin signaling in tumor models to shed light on how these receptors influence key events in metastasis, including extravasation and colonization. This knowledge aids in the development of novel integrin-targeted therapies. In parallel, we explore integrin-pathogen interactions and how they can be leveraged to combat difficult-to-treat infections.

AIP has both developed and licensed an innovative portfolio of best-in-class products, formulation, and manufacturing processes. Our world-leading research and development teams are working to improve targeted radiation therapy (TRT), revolutionizing cancer treatment. AIP's approach in oncology involves the use of a peptide mimetic radio-conjugate utilizing specific isotopes for theragnostic: Gallium-68 as a diagnostic tool, and Lutetium-177 and Actinium-225 as therapeutic agents.

Certain radioisotopes possess physical characteristics that can be harnessed for diagnostic and staging purposes in the imaging of cancer or rare diseases. Meanwhile, radioisotopes emitting higher doses of alpha and beta radiation hold the potential for therapeutic applications in eradicating cancerous or diseased cells.

Changing the way we treat diseases

Licensed NIH Technology,

Developed Chemistry Methodology

2018

Conducted Preclinical Studies, filed Orphan Applications, file Intellectual Property,

Performed Clinical Trials

2019

Conducted Clinical

Trials for Oncology Assets Submitted

Orphan Drug Applications

2020

Continued Clinical Trials, Production of

Platform Technology, Filed INDs,

Submitted Patents

2021

Orphan Applications filed, Patent

Awarded, Sepsis pre-clinical study,

Progressing to Cancer Trials

2022

Completed Toxicology for Platform Technology,

Production of Biomedical Countermeasure Drug,

IND Filings for Oncology and Rare Pediatric Diseases

2023

Roseanne Satz

CEO and President

Sylvia Mergui, Ph.D.

VP of Clinical Research and Development

Greg Waterbury

VP of Strategic Development

Brian Burnett, M.S.

Director of Regulatory of Affairs

Hamid Zolata, M.D. Ph.D.

Chief Medical Officer

TARGETS

AIP is developing a diverse portfolio of technologies aimed at addressing unmet medical needs including oncology, rare pediatric ​diseases, infectious diseases, and biomedical countermeasures. Our focus is on developing innovative therapeutic and diagnostic ​solutions that are closely integrated and personalized to patients.

Our robust oncology portfolio comprises multiple theragnostic agents to enable precise diagnosis and treatment across various cancer types. These technologies are engineered to enhance patient outcomes through early and accurate cancer detection, as well as personalized therapeutic plans tailored to each patient's unique needs. By transforming detection and treatment, we aim to significantly improve survival rates and quality of life for cancer patients

Our rare disease portfolio features diagnostic agents intended to address a variety of rare and disabling childhood conditions. These novel radiopharmaceuticals are engineered to facilitate earlier and more precise diagnosis, as well as tailored treatment plans that can dramatically improve quality of life for affected children and their families. By targeting critical unmet needs, we aim to transform the standard-of-care for numerous rare pediatric diseases.

Our infectious disease pipeline features diagnostic and therapeutic radiopharmaceuticals to facilitate rapid, precise diagnosis of various pathogenic infections, as well as personalized treatments tailored to each patient. These technologies are especially critical for emerging infectious diseases and bioterrorism threats. By transforming detection and treatment, we aim to curb outbreaks and save lives through accurate, prompt diagnosis and tailored patient care.

Our biomedical countermeasures pipeline comprises specialized drugs to bolster medical countermeasures against biological, radiological and nuclear dangers. These technologies are engineered to effectively treat acute radiation syndrome and safeguard armed forces and civilians from radiological exposure and contamination. By transforming preparedness and response, we aim to mitigate fallout and mortality from weapons of mass destruction.

There is a significant unmet need and market opportunity to develop innovative therapies across oncology, rare pediatric diseases, infectious diseases, and biomedical countermeasures.Cancer remains a leading cause of death globally, with the economic burden expected to reach $458 billion by 2030 in the United States alone. Rare pediatric diseases also present unique R&D challenges and impact millions of young lives. Meanwhile, the constant threat of drug resistant infectious diseases emphasizes the need for improved preparedness through novel diagnostics and therapeutics.

We have built a portfolio of potential drug and development candidates spanning various stages of progress.

This includes mid-stage clinical programs, development programs past IND-enabling studies, and early discovery programs.

We file Investigational New Drug (IND) applications and advance our most promising programs into formal clinical development.

A diverse portfolio of proven products

Clinical trials are research investigations designed to determine if new treatments are safe, effective, and superior to existing options. These studies adhere to strict oversight and careful evaluation protocols.

AIP is dedicated to expediting the discovery, development, and worldwide availability of transformative therapies. We concentrate on performing the clinical trials mandated by regulatory bodies to ascertain the potential risks and benefits of our investigational products. By obtaining regulatory approval, we aim to make our medications accessible to patients.

Innovation

Development

Regulatory Affairs

Innovation is the key to AIP developing novel imaging agents and targeted therapies, that can revolutionize patient treatment. By incorporating research, creativity, and a willingness to experiment, our team has made incremental improvements by radical breakthroughs in identifying patients who would benefit from our treatments.

Cooperation

Cooperation is essential to building AIP's partnerships and collaborations with other companies, academic institutions and healthcare providers. As a result, researchers can gain access to new technologies and expertise, share resources, to accelerate the development of effective novel therapies.

Development is a critical component of advancing the field of AIP's theranostics which involves design, and analysis of clinical and preclinical studies. Our team is implementing new ideas, methods, products, and therapies that can be used to identify patients who would benefit from these treatments.

Intellectual Property

Intellectual property (IP) protection is critical for companies developing diagnostics and therapeutics. By protecting our inventions, and discoveries through patents, trademarks, and other forms of IP protection, AIP establishes a competitive advantage in the market to drive progress and innovation.

Regulatory affairs play a critical role in obtaining approvals for AIP's products and technologies, to ensure that our products meet safety and efficacy standards. AIP works closely with regulatory agencies and adhere to strict cGMP regulatory controls imposed by governmental authorities managing the complex process.

Commercialization

Commercialization of our product portfolio involves partnering with pharmaceutical companies to develop effective sales and marketing campaigns generating revenue through licensing of our intellectual property (IP) , which will enable AIP to monetize products in development.

We exist to pioneer targeted therapies and advance disease detection and treatment through an integrated approach spanning proprietary tech platforms, strategic partnerships, and a patient-centric focus. Our purpose is to profoundly help patient journeys by enabling accurate diagnoses sooner and providing more powerful yet gentler treatments, giving patients the best chance for better outcomes. We want to make a meaningful difference for those impacted by complex, aggressive, rare and infectious diseases around the world.